

Practitioner's Docket No.: 802\_004 CON

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of: Patrick T. PRENDERGAST and Paul ARMSTRONG

Serial No.: Continuation of USSN 09/627,641 filed July 28, 2000

Filed: July 2, 2003

For: DITHIOLTHIONE COMPOUNDS FOR THE TREATMENT OF  
NEUROLOGICAL DISORDERS AND FOR MEMORY ENHANCEMENT

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 2, 2003 under "EXPRESS MAIL" mailing label number EV 30642 6700 US.

*Janet M. Stevens*  
Janet M. Stevens

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. These references were cited during prosecution of parent application U.S. Ser. No. 09/627,641, and copies of each of the references can be found in the PTO file for the parent application.

The above information is presented so that the Patent and Trademark Office may, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that these listed references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Respectfully submitted,

*Kevin C. Brown*

Kevin C. Brown  
Reg. No. 32,402

July 2, 2003

Date

KCB:jms

BURR & BROWN  
P.O. Box 7068  
Syracuse, NY 13261-7068

Customer No.: 025191  
Telephone: (315) 233-8300  
Facsimile: (315) 233-8320

Form PTO-1449  US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	3	Attorney Docket No.	802_004 CON

### U.S. PATENT DOCUMENTS

Exam. Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
		5,932,596	8/1999	Shih, et al.			
		5,849,782	12/1998	Beal			
		5,691,338	11/1997	Prochaska et al.			
		5,686,436	11/1997	Van Dyke			
		5,668,117	9/1997	Shapiro			
		3,994,923	11/1976	Miles, Peter et al.			

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation	Abstract
		95/01096	1/1995	WO				
		97/03055	1/1997	WO				
		199650598 B2	2/1999	AU				
		00/31060	6/2000	WO				
		98/27970	7/1998	WO				
		0 236 929A	9/1987	EP				
		0 641 792A	3/1995	EP				
		94/16563A	8/1994	WO				
		62187410	8/1987	JP				
		7112978	5/1995	JP				
		4343592	6/1995	DE				

Form PTO-1449  US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	3	Attorney Docket No.	802_004 CON

**OTHER DOCUMENTS**  
(Including Author, Title, Date, Pertinent Pages etc.)

	Benson, A., "Oltipraz: a laboratory and clinical review," <u>J. Cell Biochem., Supp.</u> 17F, pp. 278-91 (1993)
	Langouet, S., et al., "Inhibition of Human Cytochrome P450 Enzymes by 1,2-Dithiole-3-thione, Oltipraz and Its Derivatives, and Sulforaphane," <u>Chem. Res. Toxicol.</u> , Vol. 13(4), pp. 245-252 (2000)
	Fleury, M., "Action mechanism of an antischistosomal drug developed by Rhone-Poulenc Sante: 35972 RP, Oltipraz," <u>Actual. Chim.</u> , Vol. 3, pp. 123-8 (1990)
	Curphey, T., et al., "A new synthesis of 3H-1,2-dithiole-3-thiones," <u>Tetrahedron Lett.</u> , Vol. 34, pp. 3703-6 (1993)
	Maxuitenko, Y., et al., "Evaluation fo the post-initiation effects of oltipraz on aflatoxin B1-induced preneoplastic foci in a rat model of hepatic tumorigenesis," <u>Carcinogenesis</u> , Vol. 14, pp. 2423-5 (1993)
	Martens, T., et al. "Electrochemical reduction of substituted isothiazole-3-thiones in aprotic media," <u>J. Chem. Soc., Perkin Trans. 2</u> , pp. 1763-8 (1991)
	Vaccher, C., et al., "Electro-organic synthesis and x-ray crystal structure of the novel complex 2,7-dimethyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazinium triiodomercurate(II)," <u>J. Chem. Soc., Perkin Trans. 2</u> , pp. 391-4 (1989)
	Largerón, M., et al., "Studies of the reaction of substituted 1,2-dithiole-3-thiones and -3-ones with sodium cyanide in acetonitrile," <u>J. Heterocycl. Chem.</u> , Vol. 25, pp. 1223-5
	Largerón, M., et al., "Reactivity of substituted 1,2-dithiole-3-thiones with sodium ethanethiolate: a convenient route to a novel heterocycle," <u>Tetrahedron</u> , Vol. 43, pp. 3421-8 (1987)
	Fleury, M., et al., "Studies of the reaction of 1,2-dithiole-3-thiones with nucleophiles," <u>Tetrahedron</u> , Vol. 41, pp. 3705-15 (1985)
	Largerón, M., et al., "Study of the reductive metabolism pathway of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione. An electrochemical approach." <u>Tetrahedron</u> , Vol. 42, pp. 409-15 (1986)
	Van Dyke, K., "The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly," <u>Med Hypotheses</u> 1997 May; 48(5): 375-80
	Smith, Mark A., et al., "Iron accumulation in Alzheimer disease is a source of redox-generated free radicals," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 94, pp. 9866-9868 (1997)
	Ansher, S., et al., "Biochemical Effects of Dithiolthiones", <u>Fd. Chem. Toxic.</u> , Vol. 24, No. 5, pp. 405-415 (1986)
	Prochaska, H., et al., "Elevation of Glutathione Levels by Phase II Enzyme Inducers: Lack of Inhibition of Human Immunodeficiency Virus Type 1 Replication in Chronically Infected Monocytoid Cells." <u>Molecular Pharmacology</u> , Vol. 45, pp. 916-921 (1993)
	Smith, M., et al., "Widespread Peroxynitrite-Mediated Damage in Alzheimer's Disease," <u>The Journal of Neuroscience</u> , Vol. 17(8), pp. 2653-2657 (1997)
	Behl, C., et al., "Hydrogen Peroxide Mediates Amyloid $\beta$ Protein Toxicity," <u>Cell</u> , pp. 817-827, (1994)

Form PTO-1449

US DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)**Complete if Known*

Application Number

Filing Date

First Named Inventor

Patrick T. PRENDERGAST

Art Unit

Examiner Name

Confirmation No.

Sheet

3

of

3

Attorney Docket No.

802\_004 CON

Butterfield, D., et al., " $\beta$ -Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer's Disease," Biochemical and Biophysical Research Communications, Vol. 200, No. 2, pp. 710-715 (1994)

Good, P., et al., "Selective Accumulation of Aluminum and Iron in the Neurofibrillary Tangles of Alzheimer's Disease: A Laser Microprobe (LAMMA) Study," Annals of Neurology, Vol. 31, No. 3, pp. 286-292 (1992)

Drukarch, B., et al., "Drug treatment of Parkinson's disease. Time for Phase II." Biochemical Pharmacology, 59/9, 1023-1031 (2000)

Tirosh, Oren, et al., "Neuroprotective effects of alpha-lipoic acid and its positively charged amide analog", Free Radical Biol. Med. 22 (11/12), 1418-1426 (1999)

Dringen, Ralf et al., "Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cells", Naunyn-Schmiedeberg's Arch. Pharmacol. 358(6), 616-622 (1998)

Drukarch, Benjamin, et al., "Anethole dithiolethione prevents oxidative damage in glutathione-depleted astrocytes", Eur. J. Pharmacol. 329 (2/3), 259-262 (1997)

Rangan et al., British Medical Bulletin, Vol. 49, No. 3, pp. 700-718, 1993

Stoof, et al., European Journal of Pharmacology, Vo.. 375, No. 1-3, pp. 75-86, June 1999

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.